CCL18 in a multiplex urine-based assay for the detection of bladder cancer

Virginia Urquidi, Jeongsoon Kim, Myron Chang, Yunfeng Dai, Charles J. Rosser, Steven Goodison

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The early detection of bladder cancer (BCa) is pivotal for successful patient treatment and management. Through genomic and proteomic studies, we have identified a number of bladder cancer-associated biomarkers that have potential clinical utility. In a case-control study, we examined voided urines from 127 subjects: 64 tumor-bearing subjects and 63 controls. The urine concentrations of the following proteins were assessed by enzyme-linked immunosorbent assay (ELISA); C-C motif chemokine 18 (CCL18), Plasminogen Activator Inhibitor 1 (PAI-1) and CD44. Data were compared to a commercial ELISA-based BCa detection assay (BTA-Trak

Original languageEnglish (US)
Article numbere37797
JournalPLoS One
Volume7
Issue number5
DOIs
StatePublished - May 21 2012
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Assays
Immunosorbents
urine
Urine
assays
Bearings (structural)
Enzyme-Linked Immunosorbent Assay
enzyme-linked immunosorbent assay
Patient treatment
CC Chemokines
Plasminogen Activator Inhibitor 1
Biomarkers
chemokines
Enzymes
Tumor Biomarkers
case-control studies
Early Detection of Cancer
Chemokines
Proteomics

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

CCL18 in a multiplex urine-based assay for the detection of bladder cancer. / Urquidi, Virginia; Kim, Jeongsoon; Chang, Myron; Dai, Yunfeng; Rosser, Charles J.; Goodison, Steven.

In: PLoS One, Vol. 7, No. 5, e37797, 21.05.2012.

Research output: Contribution to journalArticle

Urquidi, Virginia ; Kim, Jeongsoon ; Chang, Myron ; Dai, Yunfeng ; Rosser, Charles J. ; Goodison, Steven. / CCL18 in a multiplex urine-based assay for the detection of bladder cancer. In: PLoS One. 2012 ; Vol. 7, No. 5.
@article{6fb2c66ce67147379e082d8896bb3491,
title = "CCL18 in a multiplex urine-based assay for the detection of bladder cancer",
abstract = "The early detection of bladder cancer (BCa) is pivotal for successful patient treatment and management. Through genomic and proteomic studies, we have identified a number of bladder cancer-associated biomarkers that have potential clinical utility. In a case-control study, we examined voided urines from 127 subjects: 64 tumor-bearing subjects and 63 controls. The urine concentrations of the following proteins were assessed by enzyme-linked immunosorbent assay (ELISA); C-C motif chemokine 18 (CCL18), Plasminogen Activator Inhibitor 1 (PAI-1) and CD44. Data were compared to a commercial ELISA-based BCa detection assay (BTA-Trak",
author = "Virginia Urquidi and Jeongsoon Kim and Myron Chang and Yunfeng Dai and Rosser, {Charles J.} and Steven Goodison",
year = "2012",
month = "5",
day = "21",
doi = "10.1371/journal.pone.0037797",
language = "English (US)",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - CCL18 in a multiplex urine-based assay for the detection of bladder cancer

AU - Urquidi, Virginia

AU - Kim, Jeongsoon

AU - Chang, Myron

AU - Dai, Yunfeng

AU - Rosser, Charles J.

AU - Goodison, Steven

PY - 2012/5/21

Y1 - 2012/5/21

N2 - The early detection of bladder cancer (BCa) is pivotal for successful patient treatment and management. Through genomic and proteomic studies, we have identified a number of bladder cancer-associated biomarkers that have potential clinical utility. In a case-control study, we examined voided urines from 127 subjects: 64 tumor-bearing subjects and 63 controls. The urine concentrations of the following proteins were assessed by enzyme-linked immunosorbent assay (ELISA); C-C motif chemokine 18 (CCL18), Plasminogen Activator Inhibitor 1 (PAI-1) and CD44. Data were compared to a commercial ELISA-based BCa detection assay (BTA-Trak

AB - The early detection of bladder cancer (BCa) is pivotal for successful patient treatment and management. Through genomic and proteomic studies, we have identified a number of bladder cancer-associated biomarkers that have potential clinical utility. In a case-control study, we examined voided urines from 127 subjects: 64 tumor-bearing subjects and 63 controls. The urine concentrations of the following proteins were assessed by enzyme-linked immunosorbent assay (ELISA); C-C motif chemokine 18 (CCL18), Plasminogen Activator Inhibitor 1 (PAI-1) and CD44. Data were compared to a commercial ELISA-based BCa detection assay (BTA-Trak

UR - http://www.scopus.com/inward/record.url?scp=84861323704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861323704&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0037797

DO - 10.1371/journal.pone.0037797

M3 - Article

C2 - 22629457

AN - SCOPUS:84861323704

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e37797

ER -